titoli, abstracts, parole chiave >>>
Pharmacogenomics of hypertension: a genome‐wide, placebo‐controlled cross‐over study, using four classes of antihypertensive drugs

Hiltunen, Timo P. and Donner, Kati M. and Sarin, Antti‐Pekka and Saarela, Janna and Ripatti, Samuli and Chapman, Arlene B. and Gums, John G. and Gong, Yan and Cooper‐DeHoff, Rhonda M. and Frau, Francesca and Glorioso, Valeria and Zaninello, Roberta and Salvi, Erika and Glorioso, Nicola and Boerwinkle, Eric and Turner, Stephen T. and Johnson, Julie A. and Kontula, Kimmo K. (2015) Pharmacogenomics of hypertension: a genome‐wide, placebo‐controlled cross‐over study, using four classes of antihypertensive drugs. Journal of the American Heart Association, Vol. 2015 (4), e001521. eISSN 2047-9980. Article.

[img]
Preview
Full text disponibile come PDF Richiede visualizzatore di PDF come GSview, Xpdf o Adobe Acrobat Reader
Available under License Creative Commons Attribution Non-commercial.

1512Kb

DOI: 10.1161/JAHA.114.001521

Abstract

Background Identification of genetic markers of antihypertensive drug responses could assist in individualization of hypertension treatment.
Methods and Results We conducted a genome‐wide association study to identify gene loci influencing the responsiveness of 228 male patients to 4 classes of antihypertensive drugs. The Genetics of Drug Responsiveness in Essential Hypertension (GENRES) study is a double‐blind, placebo‐controlled cross‐over study where each subject received amlodipine, bisoprolol, hydrochlorothiazide, and losartan, each as a monotherapy, in a randomized order. Replication analyses were performed in 4 studies with patients of European ancestry (PEAR Study, N=386; GERA I and II Studies, N=196 and N=198; SOPHIA Study, N=372). We identified 3 single‐nucleotide polymorphisms within the ACY3 gene that showed associations with bisoprolol response reaching genome‐wide significance (P<5×10−8); however, this could not be replicated in the PEAR Study using atenolol. In addition, 39 single‐nucleotide polymorphisms showed P values of 10−5 to 10−7. The 20 top‐associated single‐nucleotide polymorphisms were different for each antihypertensive drug. None of these top single‐nucleotide polymorphisms co‐localized with the panel of >40 genes identified in genome‐wide association studies of hypertension. Replication analyses of GENRES results provided suggestive evidence for a missense variant (rs3814995) in the NPHS1 (nephrin) gene influencing losartan response, and for 2 variants influencing hydrochlorothiazide response, located within or close to the ALDH1A3 (rs3825926) and CLIC5 (rs321329) genes.
Conclusions These data provide some evidence for a link between biology of the glomerular protein nephrin and antihypertensive action of angiotensin receptor antagonists and encourage additional studies on aldehyde dehydrogenase–mediated reactions in antihypertensive drug action.

Item Type:Article
ID Code:10776
Status:Published
Refereed:Yes
Uncontrolled Keywords:Antihypertensive drugassociation studydrug responsegenome‐wide, hypertension
Subjects:Area 06 - Scienze mediche > MED/09 Medicina interna
Divisions:001 Università di Sassari > 01-a Nuovi Dipartimenti dal 2012 > Scienze Chirurgiche, Microchirurgiche e Mediche
002 Altri enti e centri di ricerca del Nord Sardegna > AOU -Azienda Ospedaliero Universitaria, Sassari
Publisher:Blackwell / Wiley
eISSN:2047-9980
Copyright Holders:© 2015 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell
Deposited On:09 Feb 2015 14:15

I documenti depositati in UnissResearch sono protetti dalle leggi che regolano il diritto d'autore

Repository Staff Only: item control page